Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preliminary efficacy and safety of Apremilast in the treatment of acne conglobata (APACCO)
2017-002612-14Phase 2Completed
- Sponsor
- Fraunhofer-Gesellschaft
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apremilast in acne conglobata (AC), sponsored by Fraunhofer-Gesellschaft. Primary endpoint: Primary efficacy. Started Feb 2019; status: completed.
02
Drugs
apremilast
03
Conditions
acne conglobata (AC)
Beyond the preview
Go deeper on 2017-002612-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002612-14.